All lobbying filings

DLA PIPER LLP (US)

Lobbying for CURRAX PHARMACEUTICALS LLC · Specialty pharmaceutical business

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Tennessee · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 4231
Treat and Reduce Obesity Act of 2025
S 1973
Treat and Reduce Obesity Act of 2025

Lobbying activity 1

Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.